Literature DB >> 17387522

Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2.

Rahul Vaidya1, Julia Carp, Anil Sethi, Stephen Bartol, Joseph Craig, Clifford M Les.   

Abstract

The use of bone morphogenetic protein-2 (rhBMP-2) in spinal fusion has increased dramatically since an FDA approval for its use in anterior lumbar fusion with the LT cage. There are several reports of its use in transforaminal lumbar interbody fusion, posterolateral fusion, and anterior cervical fusion. Reports on adverse effects of rhBMP-2 when used in spinal fusion are scarce in literature. An Institutional Review Board approved retrospective study was conducted in patients undergoing anterior spinal fusion and instrumentation following diskectomy at a single center. Forty-six consecutive patients were included. Twenty-two patients treated with rhBMP-2 and PEEK cages were compared to 24 in whom allograft spacers and demineralized bone matrix was used. Patients filled out Cervical Oswestry Scores, VAS for arm pain, neck pain, and had radiographs preoperatively as well at every follow up visit. Radiographic examination following surgery revealed end plate resorption in all patients in whom rhBMP-2 was used. This was followed by a period of new bone formation commencing at 6 weeks. In contrast, allograft patients showed a progressive blurring of end plate-allograft junction. Dysphagia was a common complication and it was significantly more frequent and more severe in patients in whom rhBMP-2 was used. Post operative swelling anterior to the vertebral body on lateral cervical spine X-ray was significantly larger in the rhBMP-2 group when measured from 1 to 6 weeks after which it was similar. These effects are possibly due to an early inflammatory response to rhBMP-2 and were observed to be dose related. With the parameters we used, there was no significant difference in the clinical outcome of patients in the two groups at 2 years. The cost of implants in patients treated with rhBMP-2 and PEEK spacers was more than three times the cost of allograft spacers and demineralized bone matrix in 1, 2, and 3-level cases. Despite providing consistently good fusion rates, we have abandoned using rhBMP-2 and PEEK cages for anterior cervical fusion, due to the side effects, high cost, and the availability of a suitable alternative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387522      PMCID: PMC2200768          DOI: 10.1007/s00586-007-0351-9

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  21 in total

1.  Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.

Authors:  Scott D Boden; James Kang; Harvinder Sandhu; John G Heller
Journal:  Spine (Phila Pa 1976)       Date:  2002-12-01       Impact factor: 3.468

Review 2.  Recombinant human bone morphogenetic protein-2: use in spinal fusion applications.

Authors:  Harvinder S Sandhu; Safdar N Khan
Journal:  J Bone Joint Surg Am       Date:  2003       Impact factor: 5.284

Review 3.  Bone morphogenetic proteins and spinal surgery.

Authors:  Harvinder S Sandhu
Journal:  Spine (Phila Pa 1976)       Date:  2003-08-01       Impact factor: 3.468

4.  Laparoscopic anterior lumbar interbody fusion with rhBMP-2: a prospective study of clinical and radiographic outcomes.

Authors:  T J Kleeman; U M Ahn; A Talbot-Kleeman
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

5.  Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion.

Authors:  Lisa B E Shields; George H Raque; Steven D Glassman; Mitchell Campbell; Todd Vitaz; John Harpring; Christopher B Shields
Journal:  Spine (Phila Pa 1976)       Date:  2006-03-01       Impact factor: 3.468

Review 6.  Safety profile for the clinical use of bone morphogenetic proteins in the spine.

Authors:  Ashley R Poynton; Joseph M Lane
Journal:  Spine (Phila Pa 1976)       Date:  2002-08-15       Impact factor: 3.468

7.  The effectiveness of rhBMP-2 in replacing autograft: an integrated analysis of three human spine studies.

Authors:  J Kenneth Burkus; Stephen E Heim; Matthew F Gornet; Thomas A Zdeblick
Journal:  Orthopedics       Date:  2004-07       Impact factor: 1.390

Review 8.  Bone morphogenetic proteins in anterior lumbar interbody fusion: old techniques and new technologies. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004.

Authors:  J Kenneth Burkus
Journal:  J Neurosurg Spine       Date:  2004-10

9.  A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate.

Authors:  David S Baskin; Patrick Ryan; Volker Sonntag; Richard Westmark; Marsha A Widmayer
Journal:  Spine (Phila Pa 1976)       Date:  2003-06-15       Impact factor: 3.468

10.  Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004.

Authors:  Praveen V Mummaneni; Jeff Pan; Regis W Haid; Gerald E Rodts
Journal:  J Neurosurg Spine       Date:  2004-07
View more
  67 in total

1.  RhBMP-2 use in lumbar fusion surgery is associated with transient immediate post-operative leg pain.

Authors:  Fiachra E Rowan; Natasha O'Malley; Ashley Poynton
Journal:  Eur Spine J       Date:  2011-12-14       Impact factor: 3.134

Review 2.  The role of NELL-1, a growth factor associated with craniosynostosis, in promoting bone regeneration.

Authors:  X Zhang; J Zara; R K Siu; K Ting; C Soo
Journal:  J Dent Res       Date:  2010-07-20       Impact factor: 6.116

3.  Intravenous and local steroid use in the management of dysphagia after anterior cervical spine surgery: a systematic review of prospective randomized controlled trails (RCTs).

Authors:  Jingwei Liu; Yiqi Zhang; Yong Hai; Nan Kang; Bo Han
Journal:  Eur Spine J       Date:  2018-11-30       Impact factor: 3.134

4.  Adverse effects of posterior lumbar interbody fusion using rhBMP-2.

Authors:  Tomislav Smoljanovic; Ivan Bojanic; Domagoj Delimar
Journal:  Eur Spine J       Date:  2009-04-08       Impact factor: 3.134

Review 5.  An update on bone substitutes for spinal fusion.

Authors:  Masashi Miyazaki; Hiroshi Tsumura; Jeffrey C Wang; Ahmet Alanay
Journal:  Eur Spine J       Date:  2009-03-12       Impact factor: 3.134

Review 6.  Current status of bone graft options for anterior interbody fusion of the cervical and lumbar spine.

Authors:  Anthony Minh Tien Chau; Lileane Liang Xu; Johnny Ho-Yin Wong; Ralph Jasper Mobbs
Journal:  Neurosurg Rev       Date:  2013-06-07       Impact factor: 3.042

Review 7.  Scaffold translation: barriers between concept and clinic.

Authors:  Scott J Hollister; William L Murphy
Journal:  Tissue Eng Part B Rev       Date:  2011-09-21       Impact factor: 6.389

Review 8.  Bone graft substitutes for spine fusion: A brief review.

Authors:  Ashim Gupta; Nitin Kukkar; Kevin Sharif; Benjamin J Main; Christine E Albers; Saadiq F El-Amin Iii
Journal:  World J Orthop       Date:  2015-07-18

9.  Complications, revision fusions, readmissions, and utilization over a 1-year period after bone morphogenetic protein use during primary cervical spine fusions.

Authors:  Adam P Goode; William J Richardson; Robin M Schectman; Timothy S Carey
Journal:  Spine J       Date:  2013-12-07       Impact factor: 4.166

10.  Bone morphogenetic protein in complex cervical spine surgery: A safe biologic adjunct?

Authors:  Darren R Lebl
Journal:  World J Orthop       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.